Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products... Show more
Cabot Corporation (CBT) shares have traded within a relatively wide band throughout mid-2026, reflecting the tug-of-war between accelerating growth in battery materials and persistent challenges in the company's core Reinforcement Materials business. After climbing from approximately $75 in late April to above $93 by late June, the stock pulled back to the $89 range in late July — a decline of roughly 4.3% over a 30-day window. The broader specialty chemicals sector has benefited from renewed industrial demand and growing interest in electrification-related materials, yet CBT remains sensitive to global tire production trends and macroeconomic uncertainty tied to geopolitical tensions in the Middle East. Trading volumes have been robust, with several sessions exceeding 700,000 shares, indicating active institutional interest.
Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts, with operations spanning the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company operates through two primary segments: Reinforcement Materials and Performance Chemicals. The Reinforcement Materials segment supplies reinforcing carbon products — primarily carbon black — used extensively in tire manufacturing and industrial rubber goods. The Performance Chemicals segment encompasses specialty carbons, fumed metal oxides, aerogel, inkjet colorants, and a rapidly growing Battery Materials product line that produces conductive carbons and dispersions for lithium-ion battery applications. Cabot's competitive advantages include a globally diversified manufacturing footprint, long-standing relationships with major tire producers such as BRDCY, proprietary technology platforms like EVOLVE Sustainable Solutions, and a growing presence in high-growth end markets including electric vehicles and battery energy storage systems.
Several meaningful developments have shaped CBT's stock performance in recent weeks. On the battery materials front, Cabot's February 2026 acquisition of Mexico Carbon Manufacturing from Bridgestone expanded its North American production capacity and operational flexibility. The company also signed a multi-year supply agreement with PowerCo SE, Volkswagen's battery manufacturing subsidiary, to supply conductive carbons and dispersions for lithium-ion battery applications — a deal expected to contribute meaningfully to growth in the segment. In its fiscal Q2 2026 results reported in early May, Cabot delivered adjusted EPS of $1.61, beating analyst expectations of $1.46, driven by an 18% year-over-year EBIT increase in Performance Chemicals. However, Reinforcement Materials EBIT declined 29% year-over-year due to lower gross profit per ton and intensifying competition in Asia Pacific. Management also announced a capacity rationalization program targeting approximately 120,000 metric tons, expected to deliver roughly $22 million in annualized cost savings by mid-2027. In June, Cabot earned an EcoVadis Platinum sustainability rating for the sixth consecutive year, reinforcing its ESG credentials. More recently, on July 9, the company declared its regular quarterly dividend and confirmed that Q3 fiscal 2026 results will be released on August 3.
Investors seeking data-driven market insights may find value in Tickeron's Trending AI Robots page, a curated section showcasing the platform's top-performing AI-powered trading bots. Tickeron offers hundreds of AI trading bots that actively trade thousands of tickers across diverse strategies, timeframes, and performance metrics. The Trending AI Robots section highlights only the most relevant and consistently strong performers, allowing users to quickly identify bots aligned with their trading style — whether focused on short-term momentum, swing trading, or longer-term trends. Each bot is supported by transparent performance data, making it easier to evaluate historical results. Explore the Trending AI Robots page to discover AI-driven trading strategies that may complement your market approach.
Looking ahead, several key factors will likely influence CBT's trajectory through the remainder of fiscal 2026. The upcoming Q3 earnings report on August 3, 2026, represents the most immediate catalyst — analysts expect adjusted EPS around $1.62, and any deviation from consensus could move the stock significantly. Investors should monitor demand trends in the Reinforcement Materials segment, particularly as tire customers navigate tariff-related uncertainty and elevated import levels in Western markets. On the growth side, Battery Materials revenue momentum and margin expansion will be closely scrutinized, with management targeting approximately $40 million in Battery Materials EBITDA for the full fiscal year. Macroeconomic variables — including energy prices, Middle East geopolitical stability, and global industrial production — add layers of uncertainty to the demand outlook. Management's $6.00 to $6.50 adjusted EPS guidance range explicitly contemplates multiple demand scenarios for the fiscal fourth quarter. Additionally, progress on the $22 million annualized cost-savings initiative from capacity rationalization and the ongoing $30 million countermeasure program will serve as important indicators of operational discipline. While consensus analyst estimates project EPS of $6.34 for fiscal 2026 and $6.93 for fiscal 2027, the wide dispersion of outcomes underscores the importance of monitoring execution across both business segments.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 31 cases where CBT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CBT advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 206 cases where CBT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 69 cases where CBT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on August 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CBT as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CBT turned negative on July 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
CBT moved below its 50-day moving average on August 04, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.818) is normal, around the industry mean (7.256). P/E Ratio (24.543) is within average values for comparable stocks, (39.219). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.443). Dividend Yield (0.021) settles around the average of (0.019) among similar stocks. P/S Ratio (1.271) is also within normal values, averaging (95.488).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CBT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a supplier of organic chemicals
Industry ChemicalsSpecialty